title: Antiangiogenic agents combined with chemotherapy in the first-line treatment of advanced non-small-cell lung cancer: overall and histology subgroup-specific meta-analysis.
abstract: OBJECTIVE
  This study investigated the overall and histology subtype-specific results of antiangiogenic agents combined with chemotherapy versus chemotherapy alone for the first-line treatment of advanced non-small-cell lung cancer (NSCLC).
  
  
  METHODS
  Literature retrieval, trial selection, data collection, and statistical analysis were performed according to the Cochrane Handbook. The outcome measures were tumor response rate, progression-free survival (PFS), overall survival (OS), and adverse effects.
  
  
  RESULTS
  13 randomized controlled trials comprising 5,451 patients were included. The meta-analysis showed a higher response rate (risk ratio (RR) 0.63, 95% confidence interval (CI) 0.53-0.74) and a significantly prolonged PFS (hazard ratio (HR) 0.75, 95% CI 0.66-0.85) and OS (HR 0.92, 95% CI 0.86-0.98) in the groups combining antiangiogenic agents with chemotherapy versus the chemotherapy alone groups. In the histology subgroup analysis, treatment with antiangiogenic agents plus chemotherapy significantly improved the RR, PFS, and OS as compared with the chemotherapy groups in patients with nonsquamous NSCLC, but not in those with squamous NSCLC. The risk of grade 3/4 thrombocytopenia, hypertension, bleeding, proteinuria, rash, diarrhea, fatigue, headache, anorexia, and febrile neutropenia was significantly increased in the antiangiogenic agent combination groups as compared with the chemotherapy groups.
  
  
  CONCLUSIONS
  The use of antiangiogenic agents in addition to chemotherapy is a valid option for the first-line treatment of advanced NSCLC. The benefit is restricted to patients with nonsquamous-cell tumors.
authors.affiliation: Department of Oncology, Tianjin Medical University General Hospital, Tianjin, China.
authors.forename: Linlin
authors.initials: L
authors.lastname: Zhang
authors.forename: Feifei
authors.initials: F
authors.lastname: Cao
authors.forename: Yan
authors.initials: Y
authors.lastname: Wang
authors.forename: Shuang
authors.initials: S
authors.lastname: Wang
authors.forename: Diansheng
authors.initials: D
authors.lastname: Zhong
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D018572:Disease-Free Survival; D004359:Drug Therapy, Combination; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D015996:Survival Rate; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab